Development of High Throughput Molecular Profiles for the Detection and Staging of Cancer

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$729,500.00
Award Year:
2003
Program:
SBIR
Phase:
Phase II
Contract:
DAMD17-03-C-0039
Award Id:
63092
Agency Tracking Number:
A022-0079
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
1015 Grandview Drive, South San Francisco, CA, 94080
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
118926596
Principal Investigator:
Dongxiao Zhang
Vice President of Genomic
(650) 583-6688
dongxiao.zhang@epitomics.com
Business Contact:
Guo-Liang Yu
President and CEO
(650) 583-6688
guoliang.yu@epitomics.com
Research Institute:
n/a
Abstract
The discovery and identification of novel tumor associated antigens (TAAs) is critical for the advancement of accurate cancer diagnosis and staging. This Small Business Innovation Research Phase II project aims to continue development and application of anovel technology, Dual Immunostaining mediated Subtractive Cloning (DISC). The technology allows molecular cloning of genes that encode tumor cell surface proteins that are structurally or quantitatively different from those in normal cells. In Phase I,the feasibility of DISC was demonstrated. We have shown that rabbit polyclonal antibodies can be used as a complex probe to discover tumor associated cell surface antigens. Using the tumor cell line HeLa S3 and primary normal human fibroblast cells,polyclonal antibodies against these cell types were purified and effectively labeled using fluorescent dyes. A highly efficient method was established to identify cell surface antigens or unique epitopes, only expressed in tumor cells.In Phase II, DISC will be further developed and used to clone TAAs for human cancers of the breast, the prostate, and the lung. Tumor cell lines, tumor tissues, corresponding normal primary cells and normal tissues will be used to clone TAA genes. In thesame process, rabbit cell lines expressing these TAAs will be obtained. Rabbit monoclonal antibodies against these TAAs will be generated from these TAA expressing cell lines. Tumor specificity of the newly discovered TAAs and commercial potential of therabbit monoclonal antibodies will be evaluated by tumor tissue arrays.In this SBIR Phase II, Epitomics will discover and develop new TAAs and rabbit monoclonal antibodies that will enable 1) the rapid identification and characterization of novel tumor antigen targets and 2) commercial development of diagnostic kits.Epitomcis will supply the TAA genes and rabbit monoclonal antibodies to cancer researchers for clinical studies, commercialize them as research reagents and further develop some of the rabbit monoclonal antibodies into products for cancer staging anddiagnosis.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government